Vasiliki Pelekanou

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

Joseph McLaughlin, Gang Han, Kurt A. Schalper et al. · JAMA Oncology · 2015 · 839 citations · Full text

Medicine, Immunology, Oncology +17

Immunological differences between primary and metastatic breast cancer

Borbála Székely, Veerle Bossuyt, Xiaofeng Li et al. · Annals of Oncology · 2018 · 374 citations · Full text

Medicine, Immunology, Oncology +17

Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERα36 and GPR30/GPER1

Vasiliki Pelekanou, Marilena Kampa, Foteini Kiagiadaki et al. · Journal of Leukocyte Biology · 2015 · 185 citations

Life Sciences, Endocrinology, Immunology +17

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

Jamaal Rehman, Gang Han, Daniel Carvajal‐Hausdorf et al. · Modern Pathology · 2016 · 166 citations · Full text

Medicine, Cancer Biology, Oncology +10

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes

Mehmet Altan, Vasiliki Pelekanou, Kurt A. Schalper et al. · Clinical Cancer Research · 2017 · 148 citations · Full text

Medicine, Immunology, Oncology +17